IDF21-0323 Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study. (April 2022) - Yang, W.; Jiang, H.; Yu, T.; Liu, M.; Deng, H.; Liqi, F.; Li, L.; Qian, L.